References
Oberg K, Modlin I, DeHerder W, et al. Biomarkers for neuroendocrine tumor disease: a delphic consensus assessment of multianalytes, genomics, circulating cells and monoanalytes. Lancet Oncol. 2015;16:e435046.
Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–60. https://doi.org/10.1016/j.annonc.2020.03.304.
Oberg K, Califano A, Strosberg JR, et al. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. Ann Oncol. 2020;31(2):202–12. https://doi.org/10.1016/j.annonc.2019.11.003.
Modlin I, Kidd M, Oberg K, et al. Early Identification of residual disease after neuroendocrine tumor resection using a liquid biopsy multigenomic mRNA signature (NETest). Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-10021-1.
Caplin ME, Ratnayake GM. Diagnostic and therapeutic advances in neuroendocrine tumours. Nat Rev Endocrinol. 2021;17(2):81–2.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
Irvin Modlin is/has been a Medical Consultant to Ipsen, Novartis, and Wren Laboratories.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Modlin, I.M. ASO Author Reflections: A Genomic Blood Test (NETest) that Informs you if the Patient has a Recurrence at the First Postoperative Visit. Ann Surg Oncol 28, 7518–7519 (2021). https://doi.org/10.1245/s10434-021-10044-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-021-10044-8